ClinicalTrials.gg
Not yet recruitingNCT04166110AIRUpdated Nov 12, 2026

Antibiotic Therapy In Respiratory Tract Infections

An interventional study of Predetermined treatment duration and Variable treatment duration in Community-Acquired Pneumonia, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Community-Acquired Pneumonia with a site in France — 11 open to participants now, 11 under way, 5 of them phase 3. Community-Acquired Pneumonia · France.

Planned enrollment
15th of 26
310 · median 327
Started
2026
with 1 other
No phase
11 of 40
3 open now
Primary completion
2028-12
later than 9 of 10 live
Registered
19th of 40
by date
Lead sponsor
6 of 40
Assistance Publique - Hôpitaux de Paris

Among the 40 studies in Community-Acquired Pneumonia with a site in France, this one is the 15th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 19th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

11 of the 40 studies in Community-Acquired Pneumonia with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Community-Acquired Pneumonia with a site in France, or all of them as a file.
02

Study summary

Primary aim: to demonstrate that stopping antibiotic treatment in patients diagnosed with acute community acquired pneumonia (CAP) based on clinical response has a non-inferior efficacy 15 days after start of treatment, compared to a conventional predetermined duration left to the physician's judgement, in adults treated in the community setting.

Secondary aims: To compare the 2 study arms on:

  1. Clinical success at late follow up (Day 30),
  2. Duration of antibiotic treatment,
  3. Frequency and severity of adverse events,
  4. Patient's pneumonia symptoms and quality of life.
Read the detailed description

Recent studies have suggested that CAP can be successfully treated by short-course antibiotic regimen when clinical improvement is rapidly obtained. Even if clinical response is obtained in 3 days in the majority of cases, it can widely vary among patients, suggesting that "one duration does not fit all". An individualized duration of therapy depending on the patient's response could help to ensure bacterial eradication while avoiding unnecessary antibiotic exposure and thus reduce antibiotic resistance. At present, this strategy has never been tested.

This is a pragmatic open label non-inferiority randomized multicenter trial with two parallel arms comparing antibiotic treatment duration left to the physician's judgement (usually 7 to 14 days), versus interruption of treatment based on the patient's clinical response defined by reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%) for 24h, after a minimum of 2 days treatment.

Recruitment and follow-up: Outpatients consulting in a private multiprofessional health center, diagnosed as having CAP and in need for antibiotics will be assessed for eligibility. Following information and signing consent, eligible patients will be included in the study. They will receive the prescription (antibiotic type and duration determined by the physician, preferably chosen according to the French guidelines) and a collection of connected devices to monitor their vital signs 2 times a day (morning and evening). Preselected patients will be randomized as soon as they meet the two following criteria: i) they have presented the stability criteria for 24h (3 consecutive vital signs recordings); ii) they have started the antibiotic treatment at least 72 hours before, with a ≥ 80% compliance, and with at least 1 intake in the last 24 hours. Each patient will then receive a telephone call from the coordinating team (or a permanent medical platform at nights, during weekends or public holidays) in order to proceed to the randomization and ensure that everything is well understood by the patient as well as the security and compliance with the strategy.

A follow-up visit with the investigator will be performed at day 15 after the start of antibiotic treatment.

The final evaluation will be performed 30 days following the start of antibiotic treatment by a telephone call from the coordinating team.

Number of subjects necessary: 310 patients.

03

Conditions studied

  • Community-Acquired Pneumonia

Keywords

  • community-acquired pneumonia
  • antibiotic therapy duration strategy
  • non-inferiority trial
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 years or more
  • Has given written
  • Affiliated to Health insurance
  • Is able to take oral treatment
  • Presenting with suspected CAP defined by the presence of at least 2 of the following diagnostic clinical criteria:

    • Fever (temperature > 38°C)
    • Dyspnea
    • Cough
    • Production of purulent sputum
    • Crackles
    • Radiological evidence of a new infiltrate (on chest X-ray or CT scan)
  • In need for antibiotic treatment targeting respiratory tract, according to the physician in charge
  • No other site of infection besides respiratory

Exclusion criteria

Exclusion Criteria:

All subjects meeting any of the following exclusion criteria at baseline will be excluded from study participation:

  • Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency)
  • Hospitalization following consultation
  • Known (asplenia, neutropenia, agammaglobulinemia, immunosuppressive treatments or (prednisolone equivalent) > 10 mg/day, transplant, myeloma, lymphoma, known and CD4\<400/mm3, sickle-cell disease, class C cirrhosis)
  • Suspected or confirmed legionellosis
  • Atrial fibrillation / constitutive tachycardia
  • Baseline oxygen saturation \< 90% or home oxygen therapy
  • More than 24 hours of antibiotics prior to consultation
  • Patients for whom the investigator plans to prescribe a fluoroquinolone (including levofloxacin) for the treatment of community-acquired pneumonia.
  • Any other infection necessitating concomitant antibiotic treatment
  • to the study antibiotics
  • Concomitant steroid treatment only for patients treated with fluoroquinolones antibiotics
  • Pre-existing aortic aneurysm or dissection, family history of aortic aneurysm or dissection, Marfan syndrome, Ehlers-Danlos syndrome, Takayasu arthritis, arterial hypertension, atherosclerosis only for patients treated with fluoroquinolones antibiotics
  • Pregnancy
  • Breastfeeding
  • \< 1 month
  • Patient under legal guardianship or without healthcare coverage
  • Homeless patient
  • Patient enrolled in another interventional clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
310 participants (estimated)

Study arms

  • Active comparator
    Physician's prescription

    Antibiotic treatment duration according to physician, following the French national guidelines (www.has-sante.fr/upload/docs/application/pdf/2024-12/reco362\_fiche\_memo\_\_durees\_antibiotherapies\_pac\_adulte\_mel\_dec\_2024.pdf )

    Drug: Predetermined treatment duration

  • Experimental
    Duration according to stability

    Antibiotic treatment duration is variable. Interruption of treatment is based on the patient reaching stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure ≥ 90mmHg, oxygen saturation ≥ 90%). Minimum of duration of antibiotic treatment: 3 days.

    Drug: Variable treatment duration

Interventions

  • DrugPredetermined treatment duration

    Antibiotic treatment duration left to the physician's judgement (following national guidelines, 7 to 14 days)

  • DrugVariable treatment duration

    Treatment duration vary according to stability criteria reaching time Patients will self-monitor 2 times a day (in the morning and in the evening) using a set of connected devices, to monitor their vital signs before any treatment intake. After at least 3 days of treatment and stability criteria obtained for the last 24 hours (i.e. 3 vital signs recording), patients will stop the antibiotic treatment.

06

What researchers measure

Primary outcomes

  1. Cure rate at day 15

    Cure rate is the number of patients who are cured, as defined by the association of 3 criteria : * Persistence of stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure \> 90mmHg; oxygen saturation ≥ 90%; normal mental status); * No additional antibiotic treatment, targeting respiratory tract infections, taken after the end of initial antibiotic treatment. Patients who are not cured or deceased as defined above will be classified as failure at Day 15

    Time frame: Day 15

Secondary outcomes

  1. Cure rate at day 30

    Cure rate is the number of patients who are cured, as defined by the association of 2 criteria: * Absence of additional antibiotic treatment needed after the end of initial antibiotic treatment. * Absence of hospitalisation related to respiratory infection

    Time frame: Day 30

  2. Duration of antibiotic treatment for the CAP and in case of other causes

    Time frame: Up to 14 days

  3. Frequency and severity of adverse events

    Time frame: through study completion, an average of 30 days

  4. Evolution of pneumonia symptoms

    Patients' evolution of pneumonia symptoms and quality of life between the 2 study arms (CAP Score / CAP Sym)

    Time frame: through study completion, an average of 30 days

  5. For the relationship between the composition of the respiratory microbiome microbiome at the start of treatment and the response to antibiotic treatment : a composite endpoint defined by the observation of one of the events characterizing the response to

    A composite endpoint defined by the observation of one of the events characterizing the response to antibiotic treatment, among: * clinical failure or; * microbiological failure or; * emergence of antibiotic resistance.

    Time frame: through study completion, an average of 30 days

  6. Time to clinical recovery (regardless of microbiological recovery or resistance failure)

    Time frame: through study completion, an average of 30 days

  7. Presence or absence of antimicrobial resistance at any point during follow-up

    Time frame: through study completion, an average of 30 days

  8. Association between specific antibiotics and respiratory microbiome evolution

    Time frame: through study completion, an average of 30 days

  9. Association between specific antibiotics and gut microbiome evolution

    Time frame: through study completion, an average of 30 days

  10. Duration of antimicrobial treatment

    Time frame: through study completion, an average of 30 days

07

Study locations

1 site
  • Unité des Maladies Infectieuses, CHU Raymond Poincaré
    Garches, Île-de-France Region 92380, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 42 non-industry interventional studies with no phase under Community-Acquired Pneumonia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 38. This study's planned 25 months is close to that.

Counting every sponsor, half of 43 studies reached it within 24 months; a quarter within 14 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Sep 2023 → Nov 2026, primary completion Dec 2025 → Dec 2028 and completion Dec 2025 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2019
First posted
Nov 18, 2019
StartEst.
Nov 2026was Sep 2023
Primary completionEst.
Dec 2028was Dec 2025
CompletionEst.
Dec 2028was Dec 2025
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Unité des Maladies Infectieuses, CHU Raymond Poincaré · Garches, France
Show 1 removed
  • Unité des Maladies Infectieuses, CHU Raymond Poincaré · Garches, France
Nov 12, 2026
Start date
Sep 2023→Nov 2026
Nov 12, 2026
Primary completion
Dec 2025→Dec 2028
Nov 12, 2026
Study completion
Dec 2025→Dec 2028
Nov 12, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedPatients for whom the investigator plans to prescribe a fluoroquinolone (including levofloxacin) for the treatment of community-acquired pneumonia.
Nov 12, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionCure rate at day 15: how it is measured was reworded
Nov 12, 2026
Secondary outcomes
1 edited, 6 added, 1 description edited
What changed in the outcomes
  • EditedDuration of antibioticantimicrobial treatmentTime frame: Up to 14 days → through study completion, an average of 30 days
  • AddedDuration of antibiotic treatment for the CAP and in case of other causesTime frame: Up to 14 days
  • AddedFor the relationship between the composition of the respiratory microbiome microbiome at the start of treatment and the response to antibiotic treatment : a composite endpoint defined by the observation of one of the events characterizing the response toTime frame: through study completion, an average of 30 days
  • AddedTime to clinical recovery (regardless of microbiological recovery or resistance failure)Time frame: through study completion, an average of 30 days
  • AddedPresence or absence of antimicrobial resistance at any point during follow-upTime frame: through study completion, an average of 30 days
  • AddedAssociation between specific antibiotics and respiratory microbiome evolutionTime frame: through study completion, an average of 30 days
  • AddedAssociation between specific antibiotics and gut microbiome evolutionTime frame: through study completion, an average of 30 days
  • DescriptionCure rate at day 30: how it is measured was reworded
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • Unité des Maladies Infectieuses, CHU Raymond Poincaré · Garches, France
    Show 1 removed
    • Unité des Maladies Infectieuses, CHU Raymond Poincaré · Garches, France
    Start date Sep 2023→Nov 2026
    Primary completion Dec 2025→Dec 2028
    Study completion Dec 2025→Dec 2028
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedPatients for whom the investigator plans to prescribe a fluoroquinolone (including levofloxacin) for the treatment of community-acquired pneumonia.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionCure rate at day 15: how it is measured was reworded
    Secondary outcomes 1 edited, 6 added, 1 description edited
    What changed in the outcomes
    • EditedDuration of antibioticantimicrobial treatmentTime frame: Up to 14 days → through study completion, an average of 30 days
    • AddedDuration of antibiotic treatment for the CAP and in case of other causesTime frame: Up to 14 days
    • AddedFor the relationship between the composition of the respiratory microbiome microbiome at the start of treatment and the response to antibiotic treatment : a composite endpoint defined by the observation of one of the events characterizing the response toTime frame: through study completion, an average of 30 days
    • AddedTime to clinical recovery (regardless of microbiological recovery or resistance failure)Time frame: through study completion, an average of 30 days
    • AddedPresence or absence of antimicrobial resistance at any point during follow-upTime frame: through study completion, an average of 30 days
    • AddedAssociation between specific antibiotics and respiratory microbiome evolutionTime frame: through study completion, an average of 30 days
    • AddedAssociation between specific antibiotics and gut microbiome evolutionTime frame: through study completion, an average of 30 days
    • DescriptionCure rate at day 30: how it is measured was reworded
    + 3 other changes: identifiers, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04166110
Responsible party
Sponsor
First posted
Nov 18, 2019
Start date
Nov 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Aurélien DINH, MD
Contact
aurelien.dinh@aphp.fr
+ 33 1 47 10 44 32
Anne-Claude CRÉMIEUX, MD, PhD
Contact
anne-claude.cremieux@aphp.fr
+ 33 1 42 49 40 15
Aurélien DINH, MD
principal investigator · Unité des Maladies Infectieuses, Hôpital Raymond Poincaré, Garches
Anne-Claude CRÉMIEUX, MD, PhD
study director · Service des maladies infectieuses, Hôpital Saint Louis, Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion